AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Karuna Therapeutics Inc (NASDAQ:KRTX)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 329.83 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 318.750/158.375 |
| EBITDA (in USD) | -448.08M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -10.93 |
| Total Assets (in USD) | 1163.334M |
|---|---|
| Total Liabilities (in USD) | 37.096M |
| Revenue TTM (in USD) | 5.932M |
| Cash (in USD) | 248.329M |
| Market Cap (in USD) | 11,991.559 M |
| Revenue Per Share TTM | 0.164 |
| Gross Profit TTM (in USD) | 10.637M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Karuna Therapeutics Inc
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Employees: 210
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Steven M. Paul M.D. | CEO, Pres & Chairman | 1951 |
| 2. | Dr. Andrew Craig Miller | Co-Founder & COO | 1982 |
| 3. | Dr. Troy A. Ignelzi | CFO & Sec. | 1968 |
| 4. | Dr. Stephen K. Brannan | Chief Medical Officer | 1956 |
| 5. | Ms. Charmaine Lykins | Chief Commercial Officer | NA |
| 6. | Dr. Alan Breier | Chair of Scientific Advisory Board & Chief Clinical Advisor | NA |
| 7. | Dr. Ronald N. Marcus M.D. | Sr. VP of Medical | 1958 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -274.918M | -143.799M | -68.511M | -43.957M | -17.512M |
| Minority Interest | - | - | - | - | - |
| Net Income | -276.336M | -143.805M | -68.554M | -44.844M | -17.512M |
| Selling General Administrative | 76.066M | 52.617M | 28.408M | 20.869M | 2.974M |
| Gross Profit | 10.637M | 36.964M | - | - | - |
| Reconciled Depreciation | 1.112M | 0.506M | 0.145M | 0.058M | 0.006M |
| Ebit | -290.788M | -143.853M | -71.816M | -45.405M | -14.485M |
| Ebitda | -289.676M | -143.151M | -68.511M | -42.877M | -14.479M |
| Depreciation And Amortization | 1.112M | 0.702M | 3.305M | 2.528M | 0.006M |
| Operating Income | -289.676M | -143.853M | -71.816M | -45.405M | -14.51M |
| Other Operating Expenses | 300.313M | 180.817M | 71.816M | 45.405M | 14.51M |
| Interest Expense | 14.178M | 0.142M | 0.145M | 0.945M | 2.583M |
| Tax Provision | 1.418M | 0.006M | 0.043M | 0M | 0M |
| Interest Income | 14.178M | 0.502M | 3.305M | 2.528M | 0.025M |
| Net Interest Income | 14.178M | 0.502M | 3.305M | 1.583M | -2.558M |
| Income Tax Expense | 1.418M | 0.006M | 0.043M | 0.887M | -0.419M |
| Total Revenue | 10.637M | 36.964M | 0M | 0M | 0M |
| Total Operating Expenses | 300.313M | 180.817M | 71.816M | 45.405M | 14.51M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 14.758M | 0.054M | 3.305M | 1.448M | -0.444M |
| Net Income From Continuing Ops | -276.336M | -143.805M | -68.554M | -43.957M | -17.512M |
| Net Income Applicable To Common Shares | -276.336M | -143.805M | -68.554M | -43.957M | -17.512M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 1163.334M | 527.671M | 347.625M | 393.024M | 92.479M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.343M | 0.708M | 1.088M | 0.485M | 0.023M |
| Total Liab | 37.096M | 25.645M | 8.694M | 3.108M | 0.909M |
| Total Stockholder Equity | 1126.238M | 502.026M | 338.931M | 389.916M | 91.57M |
| Other Current Liab | 29.285M | 16.099M | 5.144M | 2.353M | 0.538M |
| Common Stock | 0.003M | 0.003M | 0.003M | 0.003M | 0.001M |
| Capital Stock | 0.003M | 0.003M | 0.003M | 0.003M | 0.001M |
| Retained Earnings | -564.207M | -287.871M | -144.066M | -75.512M | -32.102M |
| Good Will | - | - | - | - | - |
| Other Assets | 0.69M | 0.792M | 2.577M | 0.123M | 0.123M |
| Cash | 248.329M | 206.953M | 53.048M | 208.929M | 85.526M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 33.946M | 20.213M | 6.853M | 2.958M | 0.807M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -243.001M | -199.45M | -50.363M | -208.721M | -85.424M |
| Short Term Debt | 2.282M | 2.175M | 0.844M | 0.058M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 5.328M | 7.503M | 2.685M | 0.208M | 0.102M |
| Other Stockholder Equity | 1693.732M | 790.391M | 482.955M | 72.396M | 123.678M |
| Property Plant Equipment | 3.201M | 3.092M | 0.449M | 0.195M | 0.138M |
| Total Current Assets | 1154.769M | 517.334M | 344.599M | 392.706M | 92.218M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 875.715M | 287.038M | 269.282M | 180.468M | 4.983M |
| Net Receivables | 0.057M | 1.75M | - | - | - |
| Long Term Debt | - | - | - | - | 2.516M |
| Inventory | 28.325M | 20.885M | - | - | - |
| Accounts Payable | 2.379M | 1.939M | 0.865M | 0.547M | 0.269M |
| Accumulated Other Comprehensive Income | -3.29M | -0.497M | 0.039M | 0.005M | -0.007M |
| Non Currrent Assets Other | 0.69M | 0.792M | 0.157M | 0.123M | 0.123M |
| Non Current Assets Total | 8.565M | 10.337M | 3.026M | 0.318M | 0.261M |
| Capital Lease Obligations | 5.328M | 7.503M | 2.685M | 0.208M | 0.102M |
| Long Term Debt Total | - | - | - | - | 2.516M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -586.395M | -28.606M | -89.231M | -174.22M | -5.115M |
| Total Cashflows From Investing Activities | -586.395M | -22.688M | -89.65M | -174.335M | -5.115M |
| Total Cash From Financing Activities | 855.777M | 277.575M | 3.659M | 405.283M | 27.577M |
| Net Income | -276.336M | -143.805M | -68.554M | -43.957M | -17.512M |
| Change In Cash | 41.376M | 154.009M | -155.847M | 200.025M | 7.085M |
| Begin Period Cash Flow | 207.214M | 53.205M | 209.052M | 9.027M | 1.942M |
| End Period Cash Flow | 248.59M | 207.214M | 53.205M | 209.052M | 9.027M |
| Total Cash From Operating Activities | -228.006M | -100.878M | -69.856M | -30.923M | -15.377M |
| Depreciation | 1.112M | 0.506M | 0.145M | 0.058M | 0.006M |
| Other Cashflows From Investing Activities | - | 8.99M | - | -174.22M | -4.983M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 36.402M | 7.325M | 3.693M | 404.964M | 15.877M |
| Other Cashflows From Financing Activities | 36.402M | 7.325M | 3.659M | 75.206M | 27.577M |
| Capital Expenditures | 0.915M | 3.072M | 0.419M | 0.115M | 0.132M |
| Change In Working Capital | 4.774M | 10.845M | -15.58M | 0.599M | -1.856M |
| Other Non Cash Items | -5.007M | 1.765M | 0.662M | -0.326M | 2.583M |
| Free Cash Flow | -228.921M | -103.95M | -70.275M | -31.038M | -15.509M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Capital Group Growth Fnd of Amer Comp | 2 years ago | 2425730 |
| 2. | American Funds Growth Fund of Amer A | 2 years ago | 2425730 |
| 3. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 1607661 |
| 4. | Fidelity® Growth Company | 2 years ago | 1264109 |
| 5. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1011134 |
| 6. | Vanguard Health Care Inv | 2 years ago | 900108 |
| 7. | Vanguard Small Cap Index | 2 years ago | 829883 |
| 8. | T. Rowe Price Health Sciences | 2 years ago | 742195 |
| 9. | US Small-Cap Growth II Equity Comp | 2 years ago | 699643 |
| 10. | T. Rowe Price New Horizons | 2 years ago | 686904 |
| 11. | T. Rowe Price US Mid-Cap Growth Equity | 2 years ago | 625150 |
| 12. | T. Rowe Price Mid-Cap Growth | 2 years ago | 625150 |
| 13. | Vanguard Small Cap Value Index Inv | 2 years ago | 576157 |
| 14. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 518370 |
| 15. | American Funds SMALLCAP World A | 2 years ago | 478752 |
| 16. | Fidelity® Growth Company K6 | 2 years ago | 474661 |
| 17. | SPDR® S&P Biotech ETF | 2 years ago | 431522 |
| 18. | American Funds IS® Growth 1 | 2 years ago | 399553 |
| 19. | Capital Group Growth Composite | 2 years ago | 399553 |
| 20. | T. Rowe Price Capital Appreciation | 2 years ago | 378567 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 2 years ago | 5650167 |
| 2. | Capital Research & Mgmt Co - Division 3 | 2 years ago | 3990611 |
| 3. | Vanguard Group Inc | 2 years ago | 3203585 |
| 4. | T. Rowe Price Investment Management,Inc. | 2 years ago | 2742457 |
| 5. | T. Rowe Price Associates, Inc. | 2 years ago | 2734838 |
| 6. | BlackRock Inc | 2 years ago | 1962917 |
| 7. | Sofinnova Ventures | 2 years ago | 1381149 |
| 8. | Wellington Management Company LLP | 2 years ago | 1285508 |
| 9. | Viking Global Investors LP | 2 years ago | 1131263 |
| 10. | General Atlantic Llc | 2 years ago | 986710 |
| 11. | State Street Corporation | 2 years ago | 928970 |
| 12. | Pivotal bioVenture Partners Investment Advisor LLC | 2 years ago | 797008 |
| 13. | Geode Capital Management, LLC | 2 years ago | 545073 |
| 14. | Rock Springs Capital Management LP | 2 years ago | 505433 |
| 15. | Amvescap Plc. | 2 years ago | 365134 |
| 16. | AllianceBernstein L.P. | 2 years ago | 363368 |
| 17. | Point72 Asset Management, L.P. | 2 years ago | 347800 |
| 18. | Eventide Asset Management, LLC | 2 years ago | 339840 |
| 19. | Brown Advisory Holdings Inc | 2 years ago | 322085 |
| 20. | First Light Asset Management, LLC | 2 years ago | 303137 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...